Rigel Pharmaceuticals
Rigel Pharmaceuticals: A US-based biotech firm innovating small-molecule drugs for rare diseases and cancer.
Rigel Pharmaceuticals: A US-based biotech firm innovating small-molecule drugs for rare diseases and cancer.
Rigel Pharmaceuticals, founded with a mission to discover, develop, and provide novel therapies, focuses on significantly improving the lives of patients with hematologic disorders and cancer. The company specializes in small-molecule drugs and has developed products like TAVALISSE® (fostamatinib disodium hexahydrate) for treating thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP). Rigel Pharmaceuticals serves the United States market, aiming to address unmet medical needs in rare immune diseases and cancer.
Notable figures affiliated with Rigel Pharmaceuticals include its leadership team and board members who bring extensive experience in biotechnology and pharmaceuticals. The company has attracted significant investment from venture capital firms and institutional investors. Key achievements include the successful development and FDA approval of TAVALISSE®, which has had a positive impact on patients' lives. Rigel continues to innovate in the biotech space, contributing to advancements in medical treatments for complex diseases.
Companies similar to Rigel Pharmaceuticals include Rapt Therapeutics, Gilead Sciences, Catalyst Pharmaceuticals and KalVista Pharmaceuticals.
Rigel Pharmaceuticals was founded in 1996.
Rigel Pharmaceuticals' headquarters is located in South San Francisco, CA, US.
Rigel Pharmaceuticals' most recent funding round was for $16.5M (USD) in January 2021.
As of Jan 29, 2021, Rigel Pharmaceuticals has disclosed funding of $192.5M (USD). Undisclosed round amounts are excluded.
Rigel Pharmaceuticals has 155 employees as of Feb 5, 2024.
KalVista Pharmaceuticals
kalvista.com
